BC
MREO

Boxer Capital’s Mereo BioPharma MREO Stock Holding History

Boxer Capital’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,250,000
Closed -$2.97M – 78
2023
Q2 		$2.97M Hold
2,250,000
– – 0.14% 61
2023
Q1 		$1.59M Hold
2,250,000
– – 0.08% 69
2022
Q4 		$1.69M Hold
2,250,000
– – 0.09% 64
2022
Q3 		$1.94M Hold
2,250,000
– – 0.11% 66
2022
Q2 		$2.52M Buy
+2,250,000
New +$1.74M 0.16% 63
2021
Q3 		– Sell
-6,226,673
Closed -$19.7M – 97
2021
Q2 		$19.7M Hold
6,226,673
– – 0.7% 44
2021
Q1 		$21M Hold
6,226,673
– – 0.71% 41
2020
Q4 		$22.3M Buy
6,226,673
+2,197,024
+55% +$5.5M 0.72% 39
2020
Q3 		$10.6M Hold
4,029,649
– – 0.36% 53
2020
Q2 		$12.3M Buy
4,029,649
+1,579,106
+64% +$2.79M 0.54% 44
2020
Q1 		$2.56M Buy
+2,450,543
New +$4.24M 0.17% 58

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boxer Capital's MREO Position: Q3 2023 in Review

Boxer Capital sold out of Mereo BioPharma (MREO) in Q3 2023, closing a stake of 2,250,000 shares — an estimated $2.97M sold.

Boxer Capital first reported a position in MREO in Q1 2020 and held it in 11 quarters. The position peaked at $22.3M in Q4 2020. 56 funds tracked by Wall St. Rank hold MREO as of Q3 2023.

  • Boxer Capital reported no remaining Mereo BioPharma position as of Q3 2023 after selling out during the quarter.
  • Boxer Capital sold 2,250,000 Mereo BioPharma shares in Q3 2023, an estimated $2.97M.
  • Boxer Capital first reported a position in Mereo BioPharma in Q1 2020 and held it in 11 quarters.
  • Boxer Capital's Mereo BioPharma position peaked at $22.3M in Q4 2020.
  • 56 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2023.

Based on Boxer Capital's 13F filing for Q3 2023, filed 14 Nov 2023.